Prostate Cancer

BA directly targets DDX5, inducing LDCD through the novel BA-DDX5-TFEB-ATP6V1H axis, exploiting lysosomal vulnerability in PCa. These findings underscore BA's therapeutic potential and propose lysosomal membrane destabilization as a precision treatment strategy for PCa.

The ADT-for-all strategy was dominated by the NCCN strategy. Compared with the NCCN strategy, the ArteraAI strategy lowered costs by $12,296 and improved effectiveness by 0.01 QALYs, and thus was dominant.

GPS integration enhances BCR risk stratification in the RP setting. CAPRA-G and CAPRA-SG scores quantify genomic risk and translate GPS into simple, clinically applicable tools with improved clinical utility. External validation is warranted.

In mPC, ctDNA detectability and elevated ctDNA levels are strongly associated with adverse survival. Quantitative ctDNA profiling, including assessment of key gene mutations, offers a clinically relevant tool to refine risk stratification and to support molecularly informed treatment selection and monitoring where clinically validated.

Paclitaxel remains a standard chemotherapeutic option; however, its efficacy is often limited by ATP-driven efflux pumps and βIII-tubulin overexpression. This study evaluates the anti-metastatic activity of SP-1-39 in metastatic TNBC and the therapeutic potential of combining SP-1-39 with anti-PD-L1 immune checkpoint inhibition in a PD-L1-responsive colon cancer model. Our findings provide preclinical evidence supporting SP-1-39 as a promising therapeutic agent for TNBC and other solid tumors, either as a single agent or in combination with immunotherapy.

In vivo, 21d demonstrated a favorable pharmacokinetic profile and markedly inhibited tumor growth in an mCRPC xenograft mouse model, achieving a tumor growth inhibition (TGI) rate of 62.0%. Collectively, our findings establish 21d as the first-in-class dual BRD4/AKT inhibitor, offering a promising therapeutic strategy to overcome c-Myc-associated resistance in mCRPC.

The CALLY index is an accessible and independent prognostic biomarker for OS and CRPC progression in mHSPC. Its integration into clinical assessment could enhance risk stratification and support personalized treatment planning, potentially improving long-term patient outcomes.

These findings reveal that epithelial efferocytosis is an essential mechanism that couples cell clearance and epithelial plasticity. This work establishes epithelial efferocytosis as a determinant of cell state transitions in the prostate, with implications for a direct role in castration-resistant prostate cancer and other regenerative or remodelling processes.

The combination of ARV-110 and ponatinib exerted a significant inhibitory and synergistic effect on CRPC cells. Additionally, the substantial accumulation of reactive oxygen species induced by the combination strategy was related to the joint downregulation of catalase by the two drugs through different mechanisms. In conclusion, this study described a new strategy for the treatment of CRPC and clarified the molecular mechanisms of the combination strategy, providing a new theoretical basis for the precision treatment of CRPC.

These beneficial effects were mediated by TGF-β type II receptor downregulation, which rebalanced the TGF-β1-driven Smad2/JNK activation and PI3K/AKT suppression, thereby ameliorating CCSMC dysfunction. Our results establish the potential of KP as a therapy for neurogenic ED.